Denali Therapeutics Company Top Insiders

DNLI Stock  USD 21.93  0.26  1.20%   
Denali Therapeutics' insiders are aggressively selling. The analysis of the overall insider sentiment regarding Denali Therapeutics suggests that almost all insiders are panicking. Denali Therapeutics employs about 390 people. The company is managed by 16 executives with a total tenure of roughly 26 years, averaging almost 1.0 years of service per executive, having 24.38 employees per reported executive.
Ryan Watts  CEO
President CEO, Co-Founder, Director

Denali Therapeutics' Insider Buying Vs Selling

0

 
Selling
 
Buying

Latest Trades

2025-01-07Steve E KrognesDisposed 3339 @ 20.81View
2025-01-06Ryan J WattsDisposed 29266 @ 20.22View
2025-01-02Vicki L SatoDisposed 3080 @ 20.91View
2024-11-07Vicki L SatoDisposed 1020 @ 30View
2024-10-18Ryan J WattsDisposed 40000 @ 27.69View
2024-09-30Steve E KrognesDisposed 30000 @ 29.03View
2024-07-01Steve E KrognesDisposed 30000 @ 22.12View
2024-06-13Steve E KrognesDisposed 688 @ 21.79View
2024-06-06Jennifer E CookDisposed 1458 @ 21.73View
2024-04-15Vicki L SatoDisposed 1666 @ 18.29View
2024-04-01Steve E KrognesDisposed 92500 @ 20.5View
2024-02-15Vicki L SatoDisposed 1666 @ 18.37View
2024-02-13Steve E KrognesDisposed 2750 @ 17.29View
2024-01-16Vicki L SatoDisposed 1666 @ 18.42View
Monitoring Denali Therapeutics' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
  
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Denali Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
For more detail on how to invest in Denali Stock please use our How to Invest in Denali Therapeutics guide.

Denali Therapeutics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Denali Therapeutics' future performance. Based on our forecasts, it is anticipated that Denali will maintain a workforce of under 390 employees by February 2025.
 
Covid

Denali Therapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.2381) % which means that it has lost $0.2381 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3509) %, meaning that it created substantial loss on money invested by shareholders. Denali Therapeutics' management efficiency ratios could be used to measure how well Denali Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -0.12. The current Return On Capital Employed is estimated to decrease to -0.17. As of now, Denali Therapeutics' Asset Turnover is increasing as compared to previous years.
The current Common Stock Shares Outstanding is estimated to decrease to about 86.7 M. The Denali Therapeutics' current Net Loss is estimated to increase to about (278.7 M)

Denali Therapeutics Workforce Comparison

Denali Therapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 18,534. Denali Therapeutics holds roughly 390 in number of employees claiming about 2.1% of equities under Health Care industry.

Denali Therapeutics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Denali Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Denali Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Denali Therapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2025-03-01
0.75
6
8
 650,160 
 73,659 
2024-12-01
0.4
6
15
 147,792 
 296,891 
2024-06-01
3.6
18
5
 214,812 
 97,986 
2024-03-01
0.4118
7
17
 837,840 
 187,491 
2023-09-01
0.1053
2
19
 12,526 
 64,730 
2023-06-01
1.8571
26
14
 263,650 
 186,564 
2023-03-01
0.3571
10
28
 742,920 
 201,843 
2022-12-01
0.25
1
4
 20,000 
 60,000 
2022-09-01
0.25
3
12
 107,500 
 181,656 
2022-06-01
5.6667
17
3
 233,465 
 60,000 
2022-03-01
0.7647
13
17
 719,352 
 139,903 
2021-12-01
0.0323
1
31
 100,000 
 452,938 
2021-09-01
0.0303
1
33
 9,045 
 114,936 
2021-06-01
0.5778
26
45
 182,801 
 898,272 
2021-03-01
0.1429
16
112
 639,650 
 3,290,321 
2020-12-01
0.1333
2
15
 52,906 
 633,847 
2020-09-01
0.8889
8
9
 102,572 
 1,471,681 
2020-06-01
1.0667
16
15
 147,488 
 2,867,855 
2020-03-01
1.3
13
10
 975,687 
 3,930,919 
2019-12-01
0.1765
3
17
 8,961 
 103,104 
2019-09-01
0.2857
6
21
 25,470 
 897,140 
2019-06-01
0.3103
18
58
 260,178 
 289,747 
2019-03-01
0.3387
21
62
 845,781 
 368,991 
2018-12-01
0.3
6
20
 104,322 
 209,278 
2018-09-01
0.75
3
4
 33,858 
 71,667 
2018-06-01
7.0
7
1
 172,898 
 5,918 
2018-03-01
5.0
5
1
 877,954 
 0.00 
2017-12-01
0.9474
54
57
 58,151,022 
 55,573,197 

Denali Therapeutics Notable Stakeholders

A Denali Therapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Denali Therapeutics often face trade-offs trying to please all of them. Denali Therapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Denali Therapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Ryan WattsPresident CEO, Co-Founder, DirectorProfile
Dana AndersenCTO and Manufacturing OfficerProfile
Steve KrognesTreasurer DirectorProfile
Peter ChinSenior AffairsProfile
Carole MDChief DevelopmentProfile
Mark RowenVice DevelopmentProfile
Chris WalshGeneral CounselProfile
Tyler NielsenSenior FinanceProfile
Cindy DunkleChief OfficerProfile
Joe LewcockChief OfficerProfile
Laura HansenVice RelationsProfile
Chris JDGeneral CounselProfile
Alexander MDCFO, CoFounderProfile
Marc TessierLavigneChairman CoFounderProfile
Tony EstradaSenior SciencesProfile
Katie PengChief OfficerProfile

About Denali Therapeutics Management Performance

The success or failure of an entity such as Denali Therapeutics often depends on how effective the management is. Denali Therapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Denali management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Denali management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.11)(0.12)
Return On Capital Employed(0.16)(0.17)
Return On Assets(0.11)(0.12)
Return On Equity(0.16)(0.17)

Denali Therapeutics Workforce Analysis

Traditionally, organizations such as Denali Therapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Denali Therapeutics within its industry.

Denali Therapeutics Manpower Efficiency

Return on Denali Therapeutics Manpower

Revenue Per Employee847.5K
Revenue Per Executive20.7M
Net Loss Per Employee372.4K
Net Loss Per Executive9.1M
Working Capital Per Employee2.5M
Working Capital Per Executive61.6M

Complementary Tools for Denali Stock analysis

When running Denali Therapeutics' price analysis, check to measure Denali Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Denali Therapeutics is operating at the current time. Most of Denali Therapeutics' value examination focuses on studying past and present price action to predict the probability of Denali Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Denali Therapeutics' price. Additionally, you may evaluate how the addition of Denali Therapeutics to your portfolios can decrease your overall portfolio volatility.
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
CEOs Directory
Screen CEOs from public companies around the world
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Fundamental Analysis
View fundamental data based on most recent published financial statements
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities